Abcam has announced its acquisition of Calico Biolabs, a developer of custom recombinant rabbit monoclonal antibodies for diagnostics and pharmaceutical company partners.
“This acquisition strategically expands our leadership in recombinant rabbit monoclonal antibody technology,” Joyce Young, Vice President of Custom Services, Abcam, said. “The combination of our complementary antibody engineering capabilities will further support our mission to provide our customers with access to the best antibodies for both today’s and tomorrow’s targets of interest.”
“Abcam is a recognized leader for the supply of high-quality validated antibodies, supported by an innovative approach to production and commercialization, and we are excited to be joining the team. This move will enable us to more fully support the cancer research and associated diagnostics development being carried out by our industry partners,” Jacinto Villanueva, CEO, Calico Biolabs, said.
Calico Biolabs partners with many of the leaders in the diagnostics and biopharmaceutical industries to create custom products for companion diagnostics. In addition, Calico Biolabs range of ready-made recombinant CAL antibodies for critical immuno-oncology targets will now be available at both research and commercial scale, via the Abcam global commercial network.